<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03211676</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01679-42</org_study_id>
    <nct_id>NCT03211676</nct_id>
  </id_info>
  <brief_title>Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer</brief_title>
  <acronym>THERANOVA</acronym>
  <official_title>Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer on Removal of Small and Middle Size Molecules, Inflammatory Parameters and Oxidative Stress. An Open Cross Over Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the removal of midle molecules and inflammatory
      cytokines with the Theranova-500 ™ dialyzer (medium cut-off membrane, Baxter®) versus a high
      flux dialyzer Elisio-21H ™ (High-flux membrane, Nipro®) in chronic hemodialysis.

      Evaluation of nutritional parameters, inflamatory parameters and oxidative stress will also
      be carried out.

      Finally, the investigators will compare hepcidin levels and the erythropoietin resistance
      index between the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Anticipated">December 14, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Removal of myoglobin</measure>
    <time_frame>After 3 months</time_frame>
    <description>myoglobin Reduction ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Removal of beta2 microglobulin</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction rate and clearances of beta2 microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of urea</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of urea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of creatinine</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of interleukin 6</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of interleukin 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of IL-1beta</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of IL-1beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of TNF alpha</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of TNF alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of leptin</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of alpha 1 microglobulin</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of alpha 1 microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of retinol binding protein</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of retinol binding protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of hyaluronic acid</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of hyaluronic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of FGF 23 (fibroblast growth factor 23)</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of FGF 23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of prolactin</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of prolactin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of free light chain kappa</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of free light chain kappa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal of free light chain lambda</measure>
    <time_frame>After 3 months</time_frame>
    <description>Reduction ratio and clearances of free light chain lambda</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of hepcidin</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of hepcidin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of superoxide dismutase</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of superoxide dismutase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of isoprostan</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of isoprostan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of human oxidized LDL</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of human oxidized LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of albumin</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of prealbumin</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of prealbumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of post dialysis level of albumin</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of post dialysis level of albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of level of middle molecules and albumin in the dialysate</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average level of midlle molecules and albumin in dialysate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of use of erythrpoietin</measure>
    <time_frame>After 3 months</time_frame>
    <description>Comparison of the erythropoietin resistance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of hemoglobin levels</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of predialysis hemoglobin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of CRP</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of pre dialysis level of SAA</measure>
    <time_frame>After 3 months</time_frame>
    <description>comparison of average of pre dialysis level of SAA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Dialysis Related Complication</condition>
  <condition>Dialysis Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Theranova-500</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elisio-21H</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theranova-500 dialyzer</intervention_name>
    <description>hemodialysis with Theranova-500 dialyzer.</description>
    <arm_group_label>Theranova-500</arm_group_label>
    <arm_group_label>Elisio-21H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elisio-21H</intervention_name>
    <description>hemodialysis with Elisio-21H dialyzer</description>
    <arm_group_label>Theranova-500</arm_group_label>
    <arm_group_label>Elisio-21H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patient suffering from chronic terminal renal failure excluding nephropathy with
             myelomatous cylinders, hemodialysis for more than 6 months,

          -  Patient under dialyser Elisio-21H ™ for more than 3 months

          -  Patient including the protocol scheme and able to comply with it

          -  Free subject, without guardianship or curatorship or subordination

          -  Patients benefiting from a Social Security scheme or benefiting from it through a
             third party

          -  Non-opposition given by the patient after clear and fair information on the study

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Patient with an associated pathology (evolutionary cancer, progressive infectious
             disease or chronic inflammatory disease) that may excessively influence CRP levels
             (CRP&gt; 60 mg / L)

          -  Patient following another protocol of research or period of exclusion of another
             protocol

          -  Patients not benefiting from a Social Security scheme or not benefiting from it
             through a third party

          -  Persons benefiting from enhanced protection, namely minors, persons deprived of their
             liberty by a judicial or administrative decision, persons staying in a health or
             social institution, adults under legal protection, and finally patients in emergencies
             .

          -  Pregnant or nursing women, women of childbearing age who do not have effective
             contraception (hormonal / mechanical: oral, injectable, transcutaneous, implantable,
             intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy ).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed BELMOUAZ</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed BELMOUAZ, PH</last_name>
    <phone>05.49.44.40.78</phone>
    <email>mohamed.belmouaz@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabien DUTHE</last_name>
    <phone>05.49.44.13.59</phone>
    <email>fabien.duthe@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU DE Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed BELMOUAZ</last_name>
      <phone>05.49.44.40.78</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dialyzer</keyword>
  <keyword>beta2-microglobilin</keyword>
  <keyword>myoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

